WUHAN YZY BIOPHARMA CO., LTD.

Highlights Wuhan YZY Biopharma Co., Ltd.

Equities

2496

CNE1000063C4

Market Closed - Hong Kong S.E. Other stock markets 04:08:12 2024-06-14 EDT			5-day change	1st Jan Change
7.48 ^HKD	0.00%		+0.40%	-15.96%

05-24	Wuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference	MT
05-24	Wuhan YZY Biopharma Co., Ltd. Announces Phase II Study Data of M701 for the Treatment of Malignant Ascites Presented At the 2024 ASCO Meeting	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Wuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference	05-24	MT
Wuhan YZY Biopharma Co., Ltd. Announces Phase II Study Data of M701 for the Treatment of Malignant Ascites Presented At the 2024 ASCO Meeting	05-24	CI
Wuhan YZY Biopharma Co., Ltd. Announces the First Patient Enrolled in Phase III Clinical Trial of M701	03-27	CI
Wuhan YZY Biopharma Co., Ltd. Announces the First Patient Has Recently Been Enrolled in A Phase Ii Clinical Trial of M701	03-26	CI
Wuhan YZY Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
China Evergrande Debt Troubles Drag Hong Kong Stocks; Wuhan YZY Biopharma Closes Flat, LC Logistics Slip in Debut	23-09-25	MT
Wuhan YZY Biopharma Raises HK$121 Million in Hong Kong IPO, Prices at Bottom of Range	23-09-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer